drugset / Trial / NCT01077700
Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.
Timeline
- Start
- 2010-03
- Primary completion
- 2011-07
- Completion
- 2011-07
Publications
- Results Haig GM, Bain E, Robieson W, Othman AA, Baker J, Lenz RA. A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia. Schizophr Bull. 2014 Nov;40(6):1433-42. doi: 10.1093/schbul/sbt240. Epub 2014 Feb 10.
- Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, Haig G, Hilt DC, Dunayevich E, Umbricht D, Sand M, Keefe RSE. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. Schizophr Res. 2017 Dec;190:172-179. doi: 10.1016/j.schres.2017.03.040. Epub 2017 Apr 20.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABT-288 | Small molecule | 10 mg | — |
| Subject | ABT-288 | Small molecule | 25 mg | — |
Indications
No indication recorded.